pi3k in 10

PI3K-IN-10 is a potent inhibitor of pan-PI3K (Phosphoinositide 3-kinase).

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library.

PI3K-IN-23 is a (E)-9-oxooctadec-10-en-12-ynoic acid analogue that promotes glucose uptake (EC50: 7.00 μM).

AKT-IN-10 is a potent AKT inhibitor with research potential in breast and prostate cancers. It targets protein kinase B (PKB, also known as AKT), a key component of the PI3K AKT mTOR signaling pathway that is crucial for cell growth, survival, differentiation, and metabolism.

PI3K mTOR Inhibitor-7 is a potent dual PI3K mTOR inhibitor. PI3K mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K mTOR Inhibitor-7 is able to significantly inhibit the PI3K Akt mTOR signalling pathway. PI3K mTOR Inhibitor-7 has shown potential for research in cancer diseases.

PI3K mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K mTOR inhibitor, exhibiting greater stability than gedatolisib in artificial gastric fluid. At 10 μM, PI3K mTOR Inhibitor-6 significantly inhibits the PI3K Akt mTOR signaling pathway and has shown potential for cancer research.

PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras ERK pathways, contributing to its anti-leukemic effects. The compound's antitumor efficacy is demonstrated in both a mouse MV4-11 flank xenograft model (doses of 3 and 10 mg kg; po) and an allogeneic xenograft mouse model (dose of 40 mg kg; po) [1].

Compound F27 (Antileishmanial agent-19) is an antileishmanial compound effective against L. donovani promastigotes, demonstrating an IC50 of 3.39 μM. It functions by inhibiting the Leishmania prolyl-tRNA synthetase and disrupting the host PI3K Akt CREB axis-mediated IL-10 secretion. Additionally, Compound F27 promotes autophagy-mediated apoptosis in L. donovani promastigotes and has been shown to reduce parasite burden in L.d-infected animals [1].

PI3K-IN-51, characterized as a PI3K inhibitor, exhibits IC50 values below 500 nM for p120γ and p110δ p85α (WO2016204429A1; Example 10) [1].